Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Catarina Almeida, Ulysses Diva et al.|The Lancet|2023

Cited by 264